ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2021
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.
Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Risk of myocardial infarction and heart failure in gout patients: a systematic review and meta-analysis.Journal of cardiothoracic surgery · 2025Pooled it
- Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials.Journal of the American Heart Association · 2021Pooled it
- Lower time-averaged serum uric acid was associated with increased mortality in peritoneal dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025Article
- Application and clinical efficacy of comprehensive nursing intervention in pelvic floor and bladder function recovery post-cervical cancer surgery.Pakistan journal of medical sciences · 2024Article
- Study on the clinical efficacy, safety and compliance of quality nursing intervention in the treatment of chronic heart failure combined with respiratory tract infections.Pakistan journal of medical sciences · 2024Article
- Effects of comprehensive nursing intervention on quality of life, Self-efficacy, gastrointestinal reaction and immune function of patients with breast cancer undergoing chemotherapy.Pakistan journal of medical sciences · 2024Article
- Colchicine for cardiovascular and limb risk reduction in Medicare beneficiaries with peripheral artery disease: emulation of target trials.European heart journal open · 2024Article
- Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- Correlation analysis of serum TLR4 protein levels and TLR4 gene polymorphisms in gouty arthritis patients.PloS one · 2024Article
- Review
- The Singapore Experience With Uncontrolled Gout: Unmet Needs in the Management of Patients.Cureus · 2023Review
- Article
- Article
- Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990-2022.Frontiers in cardiovascular medicine · 2023Article
- Wuling San Based on Network Pharmacology and in vivo Evidence Against Hyperuricemia via Improving Oxidative Stress and Inhibiting Inflammation.Drug design, development and therapy · 2023Article
- Gout and hyperuricaemia: modifiable cardiovascular risk factors?Frontiers in cardiovascular medicine · 2023Review
- Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease?American heart journal plus : cardiology research and practice · 2021Review
- Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.European geriatric medicine · 2021Review
- Delayed Septal Perforation as a Complication of COVID-19: A Case Report.Aesthetic plastic surgery · 2021Article
- In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.Mayo Clinic proceedings · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials, and COLCORONA trial which will shed light on its utility in COVID-19. Our aim is to review the CV use of colchicine beyond pericardial diseases, as well as CV outcomes of the available gout therapies, including allopurinol and febuxostat. The CARES trial and its surrounding controversies, which lead to the US FDA 'black box' warning on febuxostat, in addition to the recent FAST trial which contradicts this and finds febuxostat to be non-inferior, are discussed in this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.